Merck & Co Q3 2024 Adj EPS $1.57 Beats $1.51 Estimate, Sales $16.66B Beat $16.47B Estimate
Portfolio Pulse from Benzinga Newsdesk
Merck & Co reported Q3 2024 earnings per share of $1.57, surpassing the analyst estimate of $1.51, despite a 26.29% decrease from last year. Sales reached $16.66 billion, exceeding the $16.47 billion estimate and marking a 4.35% increase from the previous year.
October 31, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck & Co's Q3 2024 earnings per share of $1.57 beat expectations, though they were down from last year. Sales also exceeded estimates, showing growth from the previous year.
Merck's earnings and sales both exceeded analyst expectations, which is typically a positive indicator for stock performance. Despite a year-over-year decline in EPS, the beat on estimates and sales growth suggest a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100